OBP2A and metabolic dysfunction-associated steatotic liver disease: Taken together, these findings suggest that tirzepatide may reduce hepatic lipid uptake by down-regulating the expression of CD36 and OBP2A in the liver, thereby alleviating intrahepatic lipid accumulation in MASLD.